
Dyslipidemia as a long-term marker for survival in pulmonary embolism


Sociedade Portuguesa de Pneumologia
Lisboa, Portugal

Available in: http://www.redalyc.org/articulo.oa?id=169722515003
Dyslipidemia as a long-term marker for survival in pulmonary embolism

L. Jara-Palomares a,*, R. Otero-Candelera a, T. Elias-Hernandez a, A. Cayuela-Dominguez b, M. Ferrer-Galvan a, M.J. Alfaro c, E. Montero c, E. Barrot-Cortes a

a Medical-Surgical Unit of Respiratory Diseases, University Hospital Virgen del Rocio, Seville, Spain
b Research Unit, University Hospital Virgen del Rocío, Seville, Spain
c Emergency Unit, University Hospital Virgen del Rocio, Seville, Spain

Received 16 December 2010; accepted 10 March 2011
Available online 29 April 2011

Abstract

Objectives: To analyse survival rate after 24 months in consecutive patients with a diagnosis of PE as well as associated factors.
Methods: Prospective cohort study during a follow-up period of two years in a series of consecutive patients with PE.
Results: During the follow-up period, 34 out of 148 patients died (23%). Factors independently associated with reduced survival rate were: creatinine levels > 2 (OR, 8.8; 95% CI, 1.1 - 70.87), previous neoplasm (OR, 8.8; 95% CI, 3.69 - 20.98), dementia (OR, 6.85; 95% CI, 2.1 - 22.33) and dyslipidemia (OR, 5.07; 95% CI, 1.92 - 13.44). Forty four percent of the patients with dyslipidemia died vs. 20.8% of patients without this condition.
Conclusions: In our study dyslipidemia shows as a long-term negative prognostic marker for survival in patients with EP.

© 2011 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L. All rights reserved.

PALAVRAS-CHAVE
Dislipidemia; Doenças metabólicas lipídicas;

Dislipidemia como um marcador de longo prazo para a sobrevivência na embolia pulmonar

Resumo

Objetivos: Analisar a taxa de sobrevivência após 24 meses, em pacientes consecutivos com diagnóstico de PE, bem como fatores associados.
Introduction

Venous thromboembolic disease (VTE) is a complex condition with a multifactor aetiology in which both the clinical history of the patient and the genetic and environmental factors play a role.

Survival rate after VTE is worse than expected and it is even worse after pulmonary embolism (PE) than after deep venous thrombosis (DVT) alone. Mortality during follow-up of patients with VTE has been the subject of several research studies and it ranges from 12.5% to 37%. VTE recurrence is so often that, about 30% of patients, present recurrences in the following 10 years.

Patients with VTE show several variables associated to a decreased survival rate. From a clinical point of view, it is interesting to which those aspects can be treated.

Patients with non treated dyslipidemia have a global mortality rate a year of 9.7%. As shown by several double-blind placebo-controlled studies, the use of statins to reduce cholesterol levels significantly decrease cardiovascular risk. Lower levels of cholesterol achieved by the administration of statins may reduce the incidence of ictus in high risk populations and in patients with ictus or transient ischemic attack.

Although we have found some studies which associate dyslipidemia with a higher risk of VTE, none of these works has documented the prognostic role dyslipidemia may play in this type of patients.

In this paper, we present a long-term study of a series of consecutive patients diagnosed with PE aiming to analyse the main complications of such condition and their distribution in time and to establish the factors associated with a lower survival rate.

Material and methods

Study design

Prospective cohort study with a follow-up period of two years.

Patients

We analysed a cohort of consecutive patients diagnosed with PE from February 2003 through September 2004 at the University Hospital Virgen del Rocio in Seville.
### Table 1 Variables associated to less survival rate

<table>
<thead>
<tr>
<th>Variable</th>
<th>Survive</th>
<th>Die</th>
<th>Relative Risk</th>
<th>CI 95%</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>55 (74.3%)</td>
<td>19 (25.7%)</td>
<td>1.30</td>
<td>0.66-2.57</td>
<td>0.44 (NS)</td>
</tr>
<tr>
<td>Age &gt;70 yrs</td>
<td>52 (78.8%)</td>
<td>14 (21.2%)</td>
<td>0.85</td>
<td>0.43-1.69</td>
<td>0.65 (NS)</td>
</tr>
<tr>
<td><strong>Risk factors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hormonal therapy</td>
<td>16 (72.7%)</td>
<td>6 (27.3%)</td>
<td>1.20</td>
<td>0.50-2.90</td>
<td>0.68 (NS)</td>
</tr>
<tr>
<td>Trauma</td>
<td>13 (92.9%)</td>
<td>1 (7.1%)</td>
<td>2.52</td>
<td>0.03-1.84</td>
<td>0.17 (NS)</td>
</tr>
<tr>
<td>Surgery</td>
<td>31 (83.8%)</td>
<td>6 (16.2%)</td>
<td>0.61</td>
<td>0.25-1.48</td>
<td>0.27 (NS)</td>
</tr>
<tr>
<td>Previous neoplasm</td>
<td>14 (45.2%)</td>
<td>17 (54.8%)</td>
<td>5.07</td>
<td>2.58-9.96</td>
<td>0.000a</td>
</tr>
<tr>
<td><strong>Baseline disease</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous history of VTE</td>
<td>19 (86.4%)</td>
<td>3 (13.6%)</td>
<td>0.54</td>
<td>0.17-1.77</td>
<td>0.31 (NS)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>49 (73.1%)</td>
<td>18 (26.9%)</td>
<td>1.38</td>
<td>0.70-2.70</td>
<td>0.35 (NS)</td>
</tr>
<tr>
<td>CHF</td>
<td>19 (73.1%)</td>
<td>7 (26.9%)</td>
<td>1.16</td>
<td>0.51-2.67</td>
<td>0.72 (NS)</td>
</tr>
<tr>
<td>ACS</td>
<td>10 (58.8%)</td>
<td>7 (41.2%)</td>
<td>2.16</td>
<td>0.94-4.97</td>
<td>0.07 (NS)</td>
</tr>
<tr>
<td>Chronic air-flow obstruction</td>
<td>13 (65%)</td>
<td>7 (35%)</td>
<td>1.74</td>
<td>0.76-4.00</td>
<td>0.19 (NS)</td>
</tr>
<tr>
<td>Asthma</td>
<td>10 (90.9%)</td>
<td>1 (9.1%)</td>
<td>0.36</td>
<td>0.05-2.62</td>
<td>0.31 (NS)</td>
</tr>
<tr>
<td>ACVA</td>
<td>15 (75%)</td>
<td>5 (25%)</td>
<td>1.10</td>
<td>0.43-2.85</td>
<td>0.84 (NS)</td>
</tr>
<tr>
<td>Dementia</td>
<td>4 (50%)</td>
<td>4 (50%)</td>
<td>3.15</td>
<td>1.11-8.97</td>
<td>0.03a</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>10 (55.6%)</td>
<td>8 (44.4%)</td>
<td>2.64</td>
<td>1.19-5.3</td>
<td>0.02a</td>
</tr>
<tr>
<td>Varicose syndrome</td>
<td>23 (88.5%)</td>
<td>3 (11.5%)</td>
<td>0.42</td>
<td>0.13-1.38</td>
<td>0.15 (NS)</td>
</tr>
<tr>
<td><strong>Prognostic and evolutive characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shock rate ≥1</td>
<td>21 (72.4%)</td>
<td>9 (27.6%)</td>
<td>1.29</td>
<td>0.58-2.85</td>
<td>0.53 (NS)</td>
</tr>
<tr>
<td>pO2 &lt; 60 mmHg</td>
<td>25 (73.5%)</td>
<td>9 (26.5%)</td>
<td>1.01</td>
<td>0.50-2.43</td>
<td>0.82 (NS)</td>
</tr>
<tr>
<td>HR &gt; 90 spm</td>
<td>74 (77.9%)</td>
<td>21 (22.1%)</td>
<td>0.87</td>
<td>0.44-1.74</td>
<td>0.70 (NS)</td>
</tr>
<tr>
<td>Systolic arterial pressure &lt;100 mmHg</td>
<td>17 (77.3%)</td>
<td>5 (22.7%)</td>
<td>1.00</td>
<td>0.39-2.57</td>
<td>0.99 (NS)</td>
</tr>
<tr>
<td>Creatinine &gt;2 mg/dL</td>
<td>1 (33.3%)</td>
<td>2 (66.7%)</td>
<td>6.59</td>
<td>1.57-27.70</td>
<td>0.01a</td>
</tr>
</tbody>
</table>

CI: Confidence interval; VTE: Venous thromboembolic disease; CHF: Congestive heart failure; ACS: Acute coronary syndrome; ACVA: Acute cerebrovascular accident; pO2: Partial oxygen pressure; HR: Heart rate; p: p < 0.05 is considered as statistically significant.

Variables associated to lower survival at two years according to multivariate analysis.

Follow up of patients: In order to analyse survival rates and long term complications we followed up all patients who did not die during admission.

All patients were followed up in a monographic visit of thromboembolic disease at months 1, 3, 6, 12, 18 and 24. We noted down the date and cause of death of all the patients who died during the follow-up period.

Strategy to capture losses was divided into: 1) telephone contact with the patients who did not attend the follow-up visits, 2) Computer System for the Management of Clinical and Analytical Documentation (SIDCA) of the University Hospital Virgen del Rocio to identify episodes requiring admission or referral to other units, 3) Review of clinical histories.

**Statistical analysis**

In the statistical analysis of the results obtained we indicate both absolute and relative frequency for qualitative variables, and mean and standard deviation for quantitative variables. In case of asymmetrical distribution of the variables, we analysed median values and interquartile range. We compared the groups (deceased and non deceased) using the chi-square test (qualitative variables) considering a p value < 0.05 as statistically significant. The comparison of the Kaplan-Meier test together with the log rank test and multivariate analysis in order to control possible confusing variables, according to the Cox regression model.

**Results**

The sample obtained in our cohort was 148 patients. Half of the patients (n=74) were male. Mean age of patient was 64.2 ± 17.2 years. During the two-year follow-up period, 34 patients died (23%). The causes of death were: cancer (n=20), acute coronary syndrome (n=6), sudden death with dyspnoea (n=4), major bleeding in the digestive tract (n=1), non hemorrhagic acute cerebrovascular stroke (n=1) and unknown causes (n=2). Accumulated mortality rate reached 19.2% after one year and 29.6% after two years.

Patients (272 patients/year) were followed up for a period of 24 ± 23.8 (median ± range). 73.6% of the sample (23% dead and 3.4% lost) was followed up for 24 months.

Table (table 1) shows those variables whose possible association with less survival rate at two years has been...
analysed. Independent variables associated to less survival rate were: creatinine levels > 2 (OR, 8.8; 95% CI, 1.1 – 70.87), previous neoplasm (OR, 8.8; 95% CI, 3.69 – 20.98), dementia (OR, 6.85; 95% CI, 2.1 – 22.33) and dyslipidemia (OR, 5.07; 95% CI, 1.92 – 13.44).

The 44.45% of patients with dyslipidemia died vs. 20.8% of patients who did not show such condition (Figure 1). No significant differences were observed in relation to mean age (63.8 vs. 68.7) or gender between patients with and without dyslipidemia.

Discussion

One of the most relevant data obtained in the present study, and which contributes to its seriousness and external accuracy, is the appropriate two-year follow-up of 97% of the sample made up only of patients with PE who were consecutively and prospectively enrolled in the study.

The sample of patients was homogeneous and its distribution between genders was similar to that observed in other studies. Patient age was similar to that reported by different series in the United States, Spain and other European studies.

Reported survival rate after VTE varies widely. Such variability is probably the result of the shortcoming observed in study design: patients with negative clinical evolution, patients diagnosed in residences, age > 65 years, patients admitted to tertiary level hospitals or patients from clinical trials.

As a result, an accurate estimate of global survival rate associated to VTE cannot be obtained. Anyway mortality observed in our study is similar to other series.

The factors associated to a lower survival rate mentioned in our study had already been analysed in previous studies, as in the case of neoplasm, dementia and renal insufficiency. Dementia is considered a negative prognostic factor in new prognostic scales, but at present dyslipidemia is not included in any scale.

Figure 1  Cumulative survival in patients with and without dyslipidemia.

High serum cholesterol and LDL cholesterol levels, low HDL cholesterol levels are considered risk factors of atherothrombosis. Despite their potent effect on atherothrombosis, lipids and lipoproteins could affect haemostasis by modulating the procoagulant and fibrinolytic expression and function. Doggen et al. have shown that elevated triglycerides levels pose a higher risk (twofold) for venous thrombosis. A case-control study also reported that hypercholesterolemia is associated with a higher risk of DVT. As regards hypertriglyceridemia, results are controversial: some studies associate it with venous thrombosis, but others do not report such interplay. It is important to carry out the measurements prior to the onset of therapy because it is known that lipid levels diminish in the early days of an acute vascular episode. Finally, Tsai et al., in their analysis of cardiovascular risk factors and incidence of a first episode of VTE, concluded that some arterial risk factors, including dyslipidemia, were not associated with VTE.

All the above mentioned studies establish the association of dyslipidemia with a first episode of VTE, but we report an association of dyslipidemia, as an independent risk factor, with lower long-term survival rate in patients with PE.

The interplay between dyslipidemia and PE in this sense has not been thoroughly analysed yet. In our series, long-term mortality rate due to vascular reasons in patients with dyslipidemia who have suffered PE is sevenfold greater than mortality in untreated dyslipidemic patients. Moreover, mortality rate observed in our patients with PE is more than twofold greater in patients with dyslipidemia than in those without this condition. We do not know for sure whether the fact of having suffered an episode of PE boosts the effect of dyslipidemia as a prognostic factor for lower survival. Nor do we know whether patients with dyslipidemia who suffer PE are those with a more advanced or difficult to manage metabolic disease. Other questions we should answer would be: which parameters defined as dyslipidemia are considered more determinant and whether the prognosis of these patients may improve with statin therapy. The last question would have significant practical implications. If we already know that statin therapy in dyslipidemic patients reduces mortality in 12.37% a year, disregard of the cause of death. This work has several limitations. Firstly, the sample of patients included in our study is not large but the results, on this issue could answer many of the above mentioned questions. Secondly, other data not available and would be interesting to contrast with the results obtained are quantitative results of total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, duplication of tests and if analytical was fasting or not, and whether the patient was taking statins. Individuals treated with lipid-lowering drugs should be excluded or taking into account, because treatment could affect lipid levels. Several studies, including ours, did not make such exclusion. These data were considered when designing the study. The development of prospective studies should collect these data.

We think that this finding also becomes more important due mainly to two recently published papers. Khemasuwan et al. suggest that the use of statins is associated with a significant reduction in the occurrence of venous thromboembolism in patients with cancer. Glynn et al.
randomized trial of apparently healthy persons found that rosuvastatin significantly reduced the occurrence of symptomatic venous thromboembolism\(^\text{17}\). These previous results in addition to our work open a field of research on whether this type of Venous Thromboembolism patients may benefit from treatment with statins.

**Conclusion**

We could summarize that in our study, patients with dyslipidemia who suffered PE showed worse survival rate. The role dyslipidemia may have as a vascular risk factor especially in patients with PE and the possibility to improve survival rates warrants further investigation.

**Conflict of interests**

Authors declare that they don’t have any conflict of interests.

**References**